It’s a veritable cornucopia of cardiology!
TARGET-FIRST and NEO-MINDSET seem to indicate it is safe to stop dual-antiplatelet therapy after 1 month following PCI for STEMI.
DanGer-Shock presented long-term follow-up for microaxial flow pumps, showing the early survival advantage was durable out to one year.
HI-PRO shows longer-term apixaban prevents VTE for that term, with the obvious counterbalancing risk of additional episodes of bleeding.
AQUATIC resoundingly discourages adding aspirin to long-term anticoagulation in patients with severe coronary artery disease.
BaxHTN is a puff piece showing baxdrostat does improve treatment-resistant hypertension, but with frequent episodes of hyperkalemia requiring medical intervention.
ESSENCE-TIMI 73b shows olezarsen reduces hypertriglyceridemia with an apparently safe adverse event profile.
MAPLE-HCM seems to safely improve functional capacity in severe heart failure, as compared to metoprolol monotherapy.
DIGIT-HF indicates digitoxin (not digoxin!) improved symptoms and survival in patients with severe heart failure.
BETAMI–DANBLOCK and REBOOT-CNIC offer duelling outcomes for whether beta-blockers should be used after myocardial infarction without reduced ejection fracture.
RETREAT-FRAIL tried to explore whether elderly patients could have their antihypertensives discontinued as part of a deprescribing effort, but didn’t conclusively show much because care in both arms remained similar.
Many of these are biased by their funders and likely exaggerate their efficacy in a general population, but plenty of fodder for discussion, regardless.